Advertisement
Screener

ENLIVEN THERAPEUTICS, INC. (ELVN) Interest Income (Expense), Nonoperating, Net

2.8 / 5 stars · 68/120 Roast Me

ENLIVEN THERAPEUTICS, INC. Interest Income (Expense), Nonoperating, Net

ENLIVEN THERAPEUTICS, INC. (ELVN) reported Interest Income (Expense), Nonoperating, Net of $4.73 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.

Financial Statements › Income Statement › Other Income

us-gaap:InterestIncomeExpenseNonoperatingNet · last filed 2026-08-05

  • ENLIVEN THERAPEUTICS, INC. interest income (expense), nonoperating, net for the quarter ending 2026-06-30 was $4.73M, a 45.56% increase year-over-year.
  • ENLIVEN THERAPEUTICS, INC. interest income (expense), nonoperating, net for the quarter ending 2026-03-31 was $4.20M, a 31.29% increase year-over-year.
  • ENLIVEN THERAPEUTICS, INC. interest income (expense), nonoperating, net for the quarter ending 2025-12-31 was $4.62M, a 24.27% increase year-over-year.
  • ENLIVEN THERAPEUTICS, INC. interest income (expense), nonoperating, net for the quarter ending 2025-09-30 was $4.95M, a 28.89% increase year-over-year.
  • ENLIVEN THERAPEUTICS, INC. interest income (expense), nonoperating, net for fiscal 2025 was $16.01M, a 7.53% increase from fiscal 2024.
  • ENLIVEN THERAPEUTICS, INC. interest income (expense), nonoperating, net for fiscal 2024 was $14.89M, a 24.43% increase from fiscal 2023.
  • ENLIVEN THERAPEUTICS, INC. interest income (expense), nonoperating, net for fiscal 2023 was $11.97M, a 959.96% increase from fiscal 2022.
  • ENLIVEN THERAPEUTICS, INC. interest income (expense), nonoperating, net for fiscal 2022 was $1.13M.
Period endInterest Income (Expense), Nonoperating, Net 3 monthInterest Income (Expense), Nonoperating, Net 3 month as first filedInterest Income (Expense), Nonoperating, Net 6 monthInterest Income (Expense), Nonoperating, Net 6 month as first filedInterest Income (Expense), Nonoperating, Net 9 monthInterest Income (Expense), Nonoperating, Net 9 month as first filedInterest Income (Expense), Nonoperating, Net 12 monthInterest Income (Expense), Nonoperating, Net 12 month as first filed
2026-06-30$4.73M
10-Q · filed 2026-08-05
$8.93M
10-Q · filed 2026-08-05
$13.55M
derived: sum of 3 quarters · filed 2026-08-05
$18.49M
derived: sum of 4 quarters · filed 2026-08-05
2026-03-31$4.20M
10-Q · filed 2026-05-07
$8.81M
derived: sum of 2 quarters · filed 2026-05-07
$13.76M
derived: sum of 3 quarters · filed 2026-05-07
$17.01M
derived: sum of 4 quarters · filed 2026-08-05
2025-12-31$4.62M
derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-03
$9.57M
derived: sum of 2 quarters · filed 2026-03-03
$12.82M
derived: sum of 3 quarters · filed 2026-08-05
$16.01M
10-K · filed 2026-03-03
2025-09-30$4.95M
10-Q · filed 2025-11-12
$8.20M
derived: sum of 2 quarters · filed 2026-08-05
$11.39M
10-Q · filed 2025-11-12
$15.11M
derived: sum of 4 quarters · filed 2026-08-05
2025-06-30$3.25M
10-Q · filed 2026-08-05
$6.45M
10-Q · filed 2026-08-05
$10.16M
derived: sum of 3 quarters · filed 2026-08-05
$14.00M
derived: sum of 4 quarters · filed 2026-08-05
2025-03-31$3.20M
10-Q · filed 2026-05-07
$6.91M
derived: sum of 2 quarters · filed 2026-05-07
$10.75M
derived: sum of 3 quarters · filed 2026-05-07
$14.84M
derived: sum of 4 quarters · filed 2026-05-07
2024-12-31$3.72M
derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-03
$7.55M
derived: sum of 2 quarters · filed 2026-03-03
$11.64M
derived: sum of 3 quarters · filed 2026-03-03
$14.89M
10-K · filed 2026-03-03
2024-09-30$3.84M
10-Q · filed 2025-11-12
$7.92M
derived: sum of 2 quarters · filed 2025-11-12
$11.18M
10-Q · filed 2025-11-12
$14.54M
derived: sum of 4 quarters · filed 2025-11-12
2024-06-30$4.09M
10-Q · filed 2025-08-13
$7.34M
10-Q · filed 2025-08-13
$10.70M
derived: sum of 3 quarters · filed 2025-08-13
$14.20M
derived: sum of 4 quarters · filed 2025-08-13
2024-03-31$3.25M
10-Q · filed 2025-05-14
$6.62M
derived: sum of 2 quarters · filed 2025-05-14
$10.11M
derived: sum of 3 quarters · filed 2025-05-14
$13.52M
derived: sum of 4 quarters · filed 2025-05-14
2023-12-31$3.37M
derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-13
$6.86M
derived: sum of 2 quarters · filed 2025-03-13
$10.27M
derived: sum of 3 quarters · filed 2025-03-13
$11.97M
10-K · filed 2025-03-13
2023-09-30$3.49M
10-Q · filed 2024-11-13
$6.91M
derived: sum of 2 quarters · filed 2024-11-13
$8.60M
10-Q · filed 2024-11-13
$9.21M
derived: sum of 4 quarters · filed 2024-11-13
2023-06-30$3.41M
10-Q · filed 2024-08-13
$5.11M
10-Q · filed 2024-08-13
$5.72M
derived: sum of 3 quarters · filed 2024-08-13
$6.10M
derived: sum of 4 quarters · filed 2024-08-13
2023-03-31$1.69M
10-Q · filed 2024-05-14
$2.31M
derived: sum of 2 quarters · filed 2024-05-14
$2.69M
derived: sum of 3 quarters · filed 2024-05-14
$2.81M
derived: sum of 4 quarters · filed 2024-05-14
2022-12-31$613.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-14
$993.00K
derived: sum of 2 quarters · filed 2024-03-14
$1.12M
derived: sum of 3 quarters · filed 2024-03-14
$1.13M
10-K · filed 2024-03-14
$943.00K
10-K · filed 2023-02-10
2022-09-30$380.00K
10-Q · filed 2023-11-09
$242.00K
10-Q · filed 2022-10-25
$507.00K
derived: sum of 2 quarters · filed 2023-11-09
$516.00K
10-Q · filed 2023-11-09
$430.00K
10-Q · filed 2022-10-25
$377.00K
derived: sum of 4 quarters · filed 2023-11-09
2022-06-30$127.00K
10-Q · filed 2023-08-10
$110.00K
10-Q · filed 2022-08-03
$136.00K
10-Q · filed 2023-08-10
$188.00K
10-Q · filed 2022-08-03
-$3.00K
derived: sum of 3 quarters · filed 2023-08-10
$27.00K
derived: sum of 4 quarters · filed 2023-08-10
2022-03-31$9.00K
10-Q · filed 2023-05-11
$78.00K
10-Q · filed 2022-05-06
-$130.00K
derived: sum of 2 quarters · filed 2023-06-23
-$100.00K
derived: sum of 3 quarters · filed 2023-06-23
-$52.00K
derived: sum of 4 quarters · filed 2023-06-23
2021-12-31-$139.00K
derived: 8-K 12 month − 10-Q 9 month · filed 2023-06-23
-$109.00K
derived: sum of 2 quarters · filed 2023-06-23
-$61.00K
derived: sum of 3 quarters · filed 2023-06-23
$22.00K
8-K · filed 2023-06-23
$233.00K
10-K · filed 2022-03-15
2021-09-30$30.00K
10-Q · filed 2022-10-25
$78.00K
derived: sum of 2 quarters · filed 2022-10-25
$161.00K
10-Q · filed 2022-10-25
$276.00K
derived: sum of 4 quarters · filed 2022-10-25
2021-06-30$48.00K
10-Q · filed 2022-08-03
$131.00K
10-Q · filed 2022-08-03
$246.00K
derived: sum of 3 quarters · filed 2022-08-03
$372.00K
derived: sum of 4 quarters · filed 2022-08-03
2021-03-31$83.00K
10-Q · filed 2022-05-06
$198.00K
derived: sum of 2 quarters · filed 2022-05-06
$324.00K
derived: sum of 3 quarters · filed 2022-05-06
$434.00K
derived: sum of 4 quarters · filed 2022-05-06
2020-12-31$115.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-15
$241.00K
derived: sum of 2 quarters · filed 2022-03-15
$351.00K
derived: sum of 3 quarters · filed 2022-03-15
$483.00K
10-K · filed 2022-03-15
2020-09-30$126.00K
10-Q · filed 2021-11-09
$236.00K
derived: sum of 2 quarters · filed 2021-11-09
$368.00K
10-Q · filed 2021-11-09
$532.00K
derived: sum of 4 quarters · filed 2021-11-09
2020-06-30$110.00K
10-Q · filed 2021-08-06
$242.00K
10-Q · filed 2021-08-06
$406.00K
derived: sum of 3 quarters · filed 2021-08-06
$660.00K
derived: sum of 4 quarters · filed 2021-08-06
2020-03-31$132.00K
10-Q · filed 2021-05-11
$296.00K
derived: sum of 2 quarters · filed 2021-05-11
$550.00K
derived: sum of 3 quarters · filed 2021-05-11
$710.00K
derived: sum of 4 quarters · filed 2021-05-11
2019-12-31$164.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-05
$418.00K
derived: sum of 2 quarters · filed 2021-03-05
$578.00K
derived: sum of 3 quarters · filed 2021-03-05
$578.00K
10-K · filed 2021-03-05
2019-09-30$254.00K
10-Q · filed 2020-11-05
$414.00K
derived: sum of 2 quarters · filed 2020-11-05
$414.00K
10-Q · filed 2020-11-05
2019-06-30$160.00K
10-Q · filed 2020-08-14
$160.00K
10-Q · filed 2020-08-14

Similar stocks

Stock NameCountryMarket CapPE Ratio
Arcutis Biotherapeutics, Inc. (ARQT)United States$3.303B115.47
Amylyx Pharmaceuticals, Inc. (AMLX)United States$3.361B-13.15
Arcus Biosciences, Inc. (RCUS)United States$3.188B-8.52
Dyne Therapeutics, Inc. (DYN)United States$3.084B-7.09
IDEAYA Biosciences, Inc. (IDYA)United States$3.540B-20.52
Organon & Co. (OGN)United States$3.603B17.03
Xenon Pharmaceuticals Inc. (XENE)$3.684B-14.27
ACADIA PHARMACEUTICALS INC (ACAD)United States$3.823B11.45
PRECIGEN, INC. (PGEN)United States$2.757B-12.94
AbCellera Biologics Inc. (ABCL)$3.879B-14.59